Your session is about to expire
← Back to Search
Verteporfin (Visudyne) for Glioblastoma
Study Summary
This trial is studying the side effects and best dose of Visudyne in treating patients with recurrent glioblastoma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2010 Phase 4 trial • 31 Patients • NCT00473642Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have swelling that improved with bevacizumab, but my tumor still grew.I have stopped any cancer treatments, including chemotherapy, at least 7 days ago.I am currently using an Optune device and want to keep using it.My MRI shows my condition is getting worse, not just changes from radiation.I am willing to have a central venous access device installed for my treatment.I have completed brain radiation at least 90 days before starting this study.I am currently on bevacizumab for my condition but it's not working, yet I can continue it in the study.I am expected to complete at least 6 weeks of treatment without significant health decline.I can care for myself but may not be able to do heavy physical work.I agree to use birth control during and 8 weeks after the study.I am not pregnant and have taken a test to confirm this before starting therapy.It has been over 3 weeks since my last major surgery.I have severe nerve-related symptoms due to brain conditions.I don't have severe health issues, except for brain tumor-related problems.I have a grade 4 glioma and have undergone standard treatment with radiation and temozolomide.I do not have hereditary porphyria.My tumor has a mutation or high levels of EGFR.My health issues, except for any nerve-related ones, are mild.
- Group 1: Treatment (verteporfin)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many people will be given this medication as part of the trial?
"That is correct, the trial information hosted on clinicaltrials.gov shows that this study is currently recruiting patients. This particular trial was first posted on 1/15/2021 and was last updated on 2/17/2022. They are looking for a total of 24 patients at 1 site."
Are people still being recruited for this experiment?
"This clinical trial, which was first posted on 1/15/2021 and most recently edited on 2/17/2022, is actively recruiting patients according to clinicaltrials.gov."
What goals do researchers hope to achieve by conducting this trial?
"The primary purpose of this study, which will run for 6 weeks, is to Response rate (RR) (Phase II). Additionally, the trial will also monitor for secondary outcomes like RR (Phase I), defined as Will be assessed by RANO for MRI of glioblastoma. Response rate will be estimated, and a 95% confidence interval will be estimated using the Clopper-Pearson method., Visudyne blood levels (Phase I), summarized descriptively using mean, median, standard deviation, and range at each time point., and PFS (Phase I), defined as Will be assessed by RANO for MRI"
What are some of the common conditions that Verteporfin is used to manage?
"Verteporfin is an effective intervention for pathologic myopia, subfoveal choroidal neovascularization (CNV), and age-related macular degeneration (AMD)."
Share this study with friends
Copy Link
Messenger